{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:40:53Z","timestamp":1781196053402,"version":"3.54.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-11254-1","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T07:36:54Z","timestamp":1751873814000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety comparison of mRNA, viral vector, and inactivated Covid-19 vaccines: incidence of adverse events following primary and booster doses among medical professionals in Malaysia"],"prefix":"10.1186","volume":"25","author":[{"given":"Rekha","family":"Prabhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girish","family":"Prabhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mila Nu Nu","family":"Htay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwathy Varadarajan","family":"Thundakattil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soe","family":"Moe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabyasachi","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"key":"11254_CR1","unstructured":"Worldometer. Malaysia COVID - Coronavirus Statistics. Available from: https:\/\/www.worldometers.info\/coronavirus\/country\/malaysia\/"},{"key":"11254_CR2","unstructured":"World Health Organization. The different types of COVID-19 vaccines. 2021 Available from: https:\/\/www.who.int\/news-room\/feature-stories\/detail\/the-race-for-a-Covid-19-vaccine-explained"},{"key":"11254_CR3","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.2147\/IDR.S315727","volume":"14","author":"MT Mascellino","year":"2021","unstructured":"Mascellino MT, Di Timoteo F, De Angelis M, et al. Overview of the main Anti-SARS-CoV-2 vaccines: mechanism of action, efficacy and safety. Infect Drug Resist. 2021;14:3459\u201376. https:\/\/doi.org\/10.2147\/IDR.S315727.","journal-title":"Infect Drug Resist"},{"key":"11254_CR4","unstructured":"Ministry of Health Malaysia. Clinical guidelines on COVID-19 vaccination in Malaysia, 4th edition. 2021 Available from: https:\/\/www.moh.gov.my"},{"issue":"25","key":"11254_CR5","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","volume":"383","author":"E Walsh","year":"2020","unstructured":"Walsh E, Frenck RW, Falsey AR, et al. Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates. N Engl J Med. 2020;383(25):2439\u201350. doi: 10\u00b71056\/NEJMoa2027906.","journal-title":"N Engl J Med"},{"key":"11254_CR6","unstructured":"Centers for Disease Control and Prevention (CDC). Selected Adverse Events Reported after COVID-19 Vaccination. Available from: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/safety\/adverse-events.html"},{"issue":"32","key":"11254_CR7","doi-asserted-by":"publisher","first-page":"4394","DOI":"10.1016\/j.vaccine.2022.05.075","volume":"40","author":"N Ab Rahman","year":"2022","unstructured":"Ab Rahman N, Lim MT, Lee FY, et al. Risk of serious adverse events after the BNT162b2, CoronaVac, and ChAdOx1 vaccines in Malaysia: A self-controlled case series study. Vaccine. 2022;40(32):4394\u2013402. https:\/\/doi.org\/10.1016\/j.vaccine.2022.05.075.","journal-title":"Vaccine"},{"issue":"6","key":"11254_CR8","doi-asserted-by":"publisher","first-page":"e1004018","DOI":"10.1371\/journal.pmed.1004018","volume":"19","author":"CKH Wong","year":"2022","unstructured":"Wong CKH, Lau KTK, Xiong X, et al. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study. PLoS Med. 2022;19(6):e1004018. https:\/\/doi.org\/10.1371\/journal.pmed.1004018.","journal-title":"PLoS Med."},{"key":"11254_CR9","doi-asserted-by":"publisher","unstructured":"Stefanizzi P, Stella P, Ancona D et al. Adverse events following Measles-Mumps-Rubella-Varicella vaccination and the case of seizures: A post marketing active surveillance in puglia Italian region, 2017\u20132018. Vaccines (Basel). 2019;7(4):140. https:\/\/doi.org\/10.3390\/vaccines7040140","DOI":"10.3390\/vaccines7040140"},{"key":"11254_CR10","unstructured":"National Pharmaceutical Regulatory Agency. Summary report on adverse events following immunization of COVID-19 vaccines in Malaysia. Malaysia: NPRA. 2023 Available from: https:\/\/www.npra.gov.my\/index.php\/en\/health-professionals\/summary-report-on-Covid-19-vaccines-aefis.html"},{"issue":"6","key":"11254_CR11","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1093\/cid\/ciac852","volume":"76","author":"JA Bettinger","year":"2023","unstructured":"Bettinger JA, Irvine MA, Shulha HP, et al. Adverse events following immunization with mRNA and viral vector vaccines in individuals with previous severe acute respiratory syndrome coronavirus 2 infection from the Canadian National Vaccine Safety Network. Clin Infect Dis. 2023;76(6):1088\u2013102. https:\/\/doi.org\/10.1093\/cid\/ciac852.","journal-title":"Clin Infect Dis."},{"issue":"5","key":"11254_CR12","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cmi.2023.12.010","volume":"30","author":"MJ Choi","year":"2024","unstructured":"Choi MJ, Na Y, Hyun HJ, et al. Comparative safety analysis of mRNA and adenoviral vector COVID-19 vaccines: A nationwide cohort study using an emulated target trial approach. Clin Microbiol Infect. 2024;30(5):646\u201352. https:\/\/doi.org\/10.1016\/j.cmi.2023.12.010.","journal-title":"Clin Microbiol Infect"},{"key":"11254_CR13","doi-asserted-by":"publisher","unstructured":"Haider S, Alvi S, Khan H et al. Common adverse eventss of Pfizer COVID-19 vaccine: An experience from Pakistan. Cureus. 2023;15(6).doi: https:\/\/doi.org\/10.7759\/cureus.40878.","DOI":"10.7759\/cureus.40878"},{"issue":"7","key":"11254_CR14","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S1473-3099(22)00146-3","volume":"22","author":"C Menni","year":"2022","unstructured":"Menni C, May A, Polidori L, et al. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID study. Lancet Infect Dis. 2022;22(7):1002\u201310. 10\u00b71016\/S1473-3099(22)00146-3.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"11254_CR15","doi-asserted-by":"publisher","first-page":"2176643","DOI":"10.1080\/21645515.2023.2176643","volume":"19","author":"L Chen","year":"2023","unstructured":"Chen L, Liang H, Liu L, et al. The association between adverse events of COVID-19 vaccination and anxiety and willingness to receive a booster dose. Hum Vaccin Immunother. 2023;19(1):2176643. https:\/\/doi.org\/10.1080\/21645515.2023.2176643.","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"11254_CR16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3390\/vaccines12010039","volume":"12","author":"AD Serbanescu-Kele","year":"2024","unstructured":"Serbanescu-Kele AD, Bouwman M, van Osch F, et al. Changes in local and systemic adverse effects following primary and booster immunization against COVID-19 in an observational cohort of Dutch healthcare workers vaccinated with BNT162b2 (Comirnaty\u00ae). Vaccines. 2024;12(1):39. doi: 10\u00b73390\/vaccines12010039.","journal-title":"Vaccines"},{"key":"11254_CR17","doi-asserted-by":"publisher","first-page":"E1447","DOI":"10.3390\/genes11121447","volume":"11","author":"T Liu","year":"2020","unstructured":"Liu T, Balzano-Nogueira L, Lleo A, et al. Transcriptional differences for COVID-19 disease map genes between males and females indicate a different basal immunophenotype relevant to the disease. Genes. 2020;11:E1447.","journal-title":"Genes"},{"key":"11254_CR18","doi-asserted-by":"publisher","first-page":"720952","DOI":"10.3389\/fimmu.2021.720952","volume":"12","author":"H Jacobsen","year":"2021","unstructured":"Jacobsen H, Klein SL. Sex differences in immunity to viral infections. Front Immunol. 2021;12:720952.","journal-title":"Front Immunol"},{"key":"11254_CR19","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s40618-020-01383-6","volume":"44","author":"C Foresta","year":"2021","unstructured":"Foresta C, Rocca MS, Di Nisio A. Gender susceptibility to COVID-19: A review of the putative role of sex hormones and X chromosome. J Endocrinol Investig. 2021;44:951\u20136.","journal-title":"J Endocrinol Investig"},{"issue":"1","key":"11254_CR20","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s43856-022-00216-2","volume":"2","author":"C Li","year":"2022","unstructured":"Li C, Bi H, Fu Z, et al. Retrospective study of the immunogenicity and safety of the coronavac SARS-CoV-2 vaccine in people with underlying medical conditions. Commun Med. 2022;2(1):151. https:\/\/doi.org\/10.1038\/s43856-022-00216-2.","journal-title":"Commun Med"},{"issue":"1","key":"11254_CR21","doi-asserted-by":"publisher","first-page":"e003777","DOI":"10.1136\/bmjdrc-2023-003777","volume":"12","author":"GA Moln\u00e1r","year":"2024","unstructured":"Moln\u00e1r GA, Vok\u00f3 Z, S\u00fct\u0151 G, et al. Effectiveness of SARS-CoV-2 primary vaccines and boosters in patients with type 2 diabetes mellitus in Hungary (HUN-VE 4 Study). BMJ Open Diabetes Res Care. 2024;12(1):e003777. https:\/\/doi.org\/10.1136\/bmjdrc-2023-003777.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"11254_CR22","unstructured":"Malaysia makes COVID-19 vaccinations compulsory for government employees. Reuters September 30, 2021. https:\/\/www.reuters.com\/world\/asia-pacific\/malaysia-makes-covid-19-vaccinations-compulsory-government-employees-2021-09-30\/"},{"issue":"4","key":"11254_CR23","doi-asserted-by":"publisher","first-page":"e0284973","DOI":"10.1371\/journal.pone.0284973","volume":"18","author":"NA Mohamed","year":"2023","unstructured":"Mohamed NA, Solehan HM, Mohd Rani MD, et al. Understanding COVID-19 vaccine hesitancy in malaysia: public perception, knowledge, and acceptance. PLoS ONE. 2023;18(4):e0284973. https:\/\/doi.org\/10.1371\/journal.pone.0284973.","journal-title":"PLoS ONE"},{"key":"11254_CR24","unstructured":"Covid-19 incidence in Malaysia. Worldometer worldometer real time world statistics on Covid-19. https:\/\/www.worldometers.info\/coronavirus\/country\/malaysia\/"},{"key":"11254_CR25","doi-asserted-by":"publisher","unstructured":"Elnaem MH, Mohd Taufek NH, Ab Rahman NS et al. COVID-19 vaccination attitudes, perceptions, and adverse events experiences in malaysia: do age, gender, and vaccine type matter? Vaccines. 2021; 9:1156. doi: https:\/\/doi.org\/10.3390\/vaccines9101156.","DOI":"10.3390\/vaccines9101156"},{"issue":"9","key":"11254_CR26","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.3390\/vaccines11091446","volume":"11","author":"F Alnaimat","year":"2023","unstructured":"Alnaimat F, Sweis JJG, Jansz J, et al. Vaccination in the era of immunosuppression. Vaccines (Basel). 2023;11(9):1446. https:\/\/doi.org\/10.3390\/vaccines11091446.","journal-title":"Vaccines (Basel)"},{"issue":"13","key":"11254_CR27","doi-asserted-by":"publisher","first-page":"2100540","DOI":"10.2807\/1560-7917","volume":"27","author":"BDS Shapiro","year":"2022","unstructured":"Shapiro BDS, Baruch Gez S, Rahamim-Cohen D, et al. Immediate side effects of Comirnaty COVID-19 vaccine: A nationwide survey of vaccinated people in israel, December 2020 to March 2021. Euro Surveill. 2022;27(13):2100540. https:\/\/doi.org\/10.2807\/1560-7917.","journal-title":"Euro Surveill"},{"key":"11254_CR28","unstructured":"World Health Organization. Coronavirus disease (COVID-19): Vaccines, WHO. 2020| Q&A updated on 08 April 2021; available from: https:\/\/www.who.int\/news-room\/q-a-detail\/coronavirus-disease-(Covid-19)-vaccines?topicsurvey=v8kj13"},{"key":"11254_CR29","unstructured":"Recipient Registration & Health Questionnaire. Contact and Demographic details. North Carolina Department of Health and Human Services. United Nations. 2021. https:\/\/covid19.ncdhhs.gov\/cvms-recipient-registration-form-01-12-2021\/open."},{"key":"11254_CR30","doi-asserted-by":"publisher","unstructured":"Riad A, Pokorn\u00e1 A, Attia S et al. Prevalence of COVID-19 vaccine adverse eventss among healthcare workers in the Czech Republic. J Clin Med. 2021; 10:1428. doi: https:\/\/doi.org\/10.3390\/jcm10071428.","DOI":"10.3390\/jcm10071428"},{"key":"11254_CR31","unstructured":"Food US, Administration D. Vaccines and related biological products advisory committee meeting - FDA briefing document: Pfizer-BioNTech COVID-19 vaccine. Silver Spring, MD: U.S. Food and Drug Administration; 2020 Available from www.fda.gov\/media\/144245\/"},{"key":"11254_CR32","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/S1473-3099(22)00054-8","volume":"22","author":"HG Rosenblum","year":"2022","unstructured":"Rosenblum HG, Gee J, Liu R, et al. Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the vaccine adverse event reporting system and v-safe. Lancet Infect Dis. 2022;22:802\u201312. doi: 10\u00b71016\/S1473-3099(22)00054-8.","journal-title":"Lancet Infect Dis"},{"key":"11254_CR33","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1473-3099(21)00224-3","volume":"21","author":"C Menni","year":"2021","unstructured":"Menni C, Klaser K, May A, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID symptom study app in the UK: A prospective observational study. Lancet Infect Dis. 2021;21:939\u201349. doi: 10\u00b71016\/S1473-3099(21)00224-3.","journal-title":"Lancet Infect Dis"},{"key":"11254_CR34","doi-asserted-by":"publisher","unstructured":"Abukhalil AD, Shatat SS, Abushehadeh RR, et al. Adverse eventss of pfizer\/biontech (BNT162b2) COVID-19 vaccine reported by the Birzeit university community. BMC Infect Dis. 2023;23(5). https:\/\/doi.org\/10.1186\/s12879-022-07974-3.","DOI":"10.1186\/s12879-022-07974-3"},{"issue":"60","key":"11254_CR35","doi-asserted-by":"publisher","first-page":"eabj9256","DOI":"10.1126\/sciimmunol.abj9256","volume":"6","author":"J Sprent","year":"2021","unstructured":"Sprent J, King C. COVID-19 vaccine adverse eventss: the positives about feeling bad. Sci Immunol. 2021;6(60):eabj9256. https:\/\/doi.org\/10.1126\/sciimmunol.abj9256.","journal-title":"Sci Immunol"},{"key":"11254_CR36","doi-asserted-by":"publisher","unstructured":"Trougakos IP, Terpos E, Alexopoulos H et al. Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis. Trends in Molecular Medicine. 2022;28(7):542\u2013\u200954. doi: https:\/\/doi.org\/10.1016\/j.molmed.2022.04.007.","DOI":"10.1016\/j.molmed.2022.04.007"},{"key":"11254_CR37","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383:2603\u201315. https:\/\/doi.org\/10.1056\/NEJMoa2034577.","journal-title":"N Engl J Med"},{"key":"11254_CR38","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41591-020-01194-5","volume":"27","author":"KJ Ewer","year":"2021","unstructured":"Ewer KJ, Barrett JR, Belij-Rammerstorfer S, et al. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1\/2 clinical trial. Nat Med. 2021;27:270\u20138. https:\/\/doi.org\/10.1038\/s41591-020-01194-5.","journal-title":"Nat Med"},{"key":"11254_CR39","doi-asserted-by":"publisher","unstructured":"Hansen KT, Povlsen FK, Bech BH et al. Immediate adverse reactions following COVID-19 vaccination among 16\u201365-year-old Danish citizens. Vaccine. 2023;41(33):4879-87. doi: https:\/\/doi.org\/10.1016\/j.vaccine.2023.06.069.","DOI":"10.1016\/j.vaccine.2023.06.069"},{"key":"11254_CR40","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1016\/j.ymthe.2021.03.020","volume":"29","author":"BM Younis","year":"2021","unstructured":"Younis BM, Osman M, Khalil EAG, et al. Safety and immunogenicity of ChAd63-KH vaccine in post-kala-azar dermal leishmaniasis patients in. Sudan Mol Ther. 2021;29:2366\u201377.","journal-title":"Sudan Mol Ther"},{"key":"11254_CR41","doi-asserted-by":"publisher","first-page":"8982","DOI":"10.1016\/j.vaccine.2011.09.039","volume":"29","author":"LM Christian","year":"2011","unstructured":"Christian LM, Iams JD, Porter K, et al. Inflammatory responses to trivalent influenza virus vaccine among pregnant women. Vaccine. 2011;29:8982\u201387. https:\/\/doi.org\/10.1016\/j.vaccine.2011.09.039.","journal-title":"Vaccine"},{"key":"11254_CR42","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/aji.12117","volume":"70","author":"LM Christian","year":"2013","unstructured":"Christian LM, Porter K, Karlsson E, et al. Serum Proinflammatory cytokine responses to influenza virus vaccine among women during pregnancy versus non-pregnancy. Am J Reprod Immunol. 2013;70:45\u201353. https:\/\/doi.org\/10.1111\/aji.12117.","journal-title":"Am J Reprod Immunol"},{"key":"11254_CR43","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1021\/acscentsci.1c00120","volume":"7","author":"Y Li","year":"2021","unstructured":"Li Y, Tenchov R, Smoot J, et al. A comprehensive review of the global efforts on COVID-19 vaccine development. ACS Cent Sci. 2021;7:512\u201333. https:\/\/doi.org\/10.1021\/acscentsci.1c00120.","journal-title":"ACS Cent Sci"},{"issue":"9","key":"11254_CR44","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1016\/j.vaccine.2024.01.100","volume":"42","author":"K Faksova","year":"2024","unstructured":"Faksova K, Walsh D, Jiang Y, et al. COVID-19 vaccines and adverse events of special interest: A multinational global vaccine data network (GVDN) cohort study of 99 million vaccinated individuals. Vaccine. 2024;42(9):2200\u201311. https:\/\/doi.org\/10.1016\/j.vaccine.2024.01.100.","journal-title":"Vaccine"},{"key":"11254_CR45","doi-asserted-by":"publisher","unstructured":"Rahman F, Dahmen A, Herzog-Hauff S et al. Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen. Hepatology. 2000;31(2):521-7. doi: https:\/\/doi.org\/10.1002\/hep.510310237.","DOI":"10.1002\/hep.510310237"},{"key":"11254_CR46","doi-asserted-by":"publisher","unstructured":"Lee SW, Moon JY, Lee SK et al. Anti-SARS-CoV-2 spike protein RBD antibody levels after receiving a second dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in healthcare workers: Lack of association with age, sex, obesity, and adverse reactions. Front Immunol. 2021; 12:779212. doi: https:\/\/doi.org\/10.3389\/fimmu.2021.779212.","DOI":"10.3389\/fimmu.2021.779212"},{"issue":"7855","key":"11254_CR47","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41586-021-03324-6","volume":"592","author":"Z Wang","year":"2021","unstructured":"Wang Z, Schmidt F, Weisblum Y, et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and Circulating variants. Nature. 2021;592(7855):616\u201322. doi: 10\u00b71038\/s41586-021-03324-6.","journal-title":"Nature"},{"issue":"10269","key":"11254_CR48","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in brazil, South africa, and the UK. Lancet. 2021;397(10269):99\u2013111.","journal-title":"Lancet"},{"issue":"44","key":"11254_CR49","doi-asserted-by":"publisher","first-page":"6485","DOI":"10.1016\/j.vaccine.2021.09.060","volume":"39","author":"VN Tran","year":"2021","unstructured":"Tran VN, Nguyen HA, Le TTA, et al. Factors influencing adverse events following immunization with AZD1222 in Vietnamese adults during first half of 2021. Vaccine. 2021;39(44):6485\u201391.","journal-title":"Vaccine"},{"key":"11254_CR50","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.sleep.2022.06.011","volume":"98","author":"BB Garrido-Su\u00e1rez","year":"2022","unstructured":"Garrido-Su\u00e1rez BB, Garrido-Valdes M, Garrido G. Reactogenic sleepiness after COVID-19 vaccination. A hypothesis involving orexinergic system linked to inflammatory signals. Sleep Med. 2022;98:79\u201386.","journal-title":"Sleep Med"},{"key":"11254_CR51","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41541-019-0132-6","volume":"4","author":"C Herv\u00e9","year":"2019","unstructured":"Herv\u00e9 C, Laup\u00e8ze B, Del Giudice G, et al. The how\u2019s and what\u2019s of vaccine reactogenicity. NPJ Vaccines. 2019;4:39. https:\/\/doi.org\/10.1038\/s41541-019-0132-6.","journal-title":"NPJ Vaccines"},{"issue":"1","key":"11254_CR52","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1590\/0001-3765201720160487","volume":"89","author":"E Fuentes","year":"2017","unstructured":"Fuentes E, Fuentes M, Alarcon M, Palomo I. Immune system dysfunction in the elderly. Acad Bras Cienc. 2017;89(1):285\u201399.","journal-title":"Acad Bras Cienc"},{"key":"11254_CR53","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.4049\/jimmunol.0901022","volume":"184","author":"F Panda","year":"2010","unstructured":"Panda F, Qian S, Mohanty D, et al. Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response. J Immunol. 2010;184:2518\u201327.","journal-title":"J Immunol"},{"issue":"8","key":"11254_CR54","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.mad.2005.03.008","volume":"126","author":"M El Yousfi","year":"2005","unstructured":"El Yousfi M, Mercier S, Breuill\u00e9 D, et al. The inflammatory response to vaccination is altered in the elderly. Mech Ageing Dev. 2005;126(8):874\u201381. 10.1016\/j. mad.2005.03.008.","journal-title":"Mech Ageing Dev"},{"key":"11254_CR55","doi-asserted-by":"publisher","first-page":"1021396","DOI":"10.3389\/fimmu.2022.1021396","volume":"13","author":"G Fedele","year":"2022","unstructured":"Fedele G, Trentini F, Schiavoni I, et al. Evaluation of humoral and cellular response to four vaccines against COVID-19 in different age groups: A longitudinal study. Front Immunol. 2022;13:1021396.","journal-title":"Front Immunol"},{"issue":"17","key":"11254_CR56","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.3346\/jkms.2021.36.e115","volume":"36","author":"S Bae","year":"2021","unstructured":"Bae S, Lee YW, Lim SY, et al. Adverse reactions following the first dose of ChAdOx1 nCoV-19 vaccine and BNT162b2 vaccine for healthcare workers in South Korea. J Korean Med Sci. 2021;36(17):e115. https:\/\/doi.org\/10.3346\/jkms.2021.36.e115.","journal-title":"J Korean Med Sci"},{"issue":"25","key":"11254_CR57","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1056\/NEJMoa2028436","volume":"383","author":"EJ Anderson","year":"2020","unstructured":"Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med. 2020;383(25):2427\u201338. https:\/\/doi.org\/10.1056\/NEJMoa2028436.","journal-title":"N Engl J Med"},{"issue":"7","key":"11254_CR58","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1007\/s10875-023-01527-2","volume":"43","author":"HA Fryer","year":"2023","unstructured":"Fryer HA, Hartley GE, Edwards ES, et al. COVID-19 adenoviral vector vaccination elicits a robust memory B cell response with the capacity to recognize Omicron BA 2 and BA 5 variants. J Clin Immunol. 2023;43(7):1506\u201318.","journal-title":"J Clin Immunol"},{"key":"11254_CR59","doi-asserted-by":"publisher","first-page":"S63","DOI":"10.1016\/j.ijid.2021.12.148","volume":"116","author":"ST Ramu","year":"2022","unstructured":"Ramu ST, Jeewandara C, Kuruppu H, et al. Memory B cell responses at 16 weeks following a single dose of AZD1222\/Covishield in Sri Lankan individuals. Int J Infect Dis. 2022;116:S63. https:\/\/doi.org\/10.1016\/j.ijid.2021.12.148.","journal-title":"Int J Infect Dis"},{"issue":"2","key":"11254_CR60","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41591-020-01194-5","volume":"27","author":"KJ Ewer","year":"2021","unstructured":"Ewer KJ, Barrett JR, Belij-Rammerstorfer S, et al. Oxford COVID vaccine trial group. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1\/2 clinical trial. Nat Med. 2021;27(2):270\u20138. https:\/\/doi.org\/10.1038\/s41591-020-01194-5.","journal-title":"Nat Med"},{"key":"11254_CR61","doi-asserted-by":"publisher","first-page":"669339","DOI":"10.3389\/fimmu.2021.669339","volume":"12","author":"Q He","year":"2021","unstructured":"He Q, Mao Q, Zhang J, et al. COVID-19 vaccines: current Understanding on immunogenicity, safety, and further considerations. Front Immunol. 2021;12:669339. https:\/\/doi.org\/10.3389\/fimmu.2021.669339.","journal-title":"Front Immunol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11254-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-11254-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11254-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T07:36:59Z","timestamp":1751873819000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-11254-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11254"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-11254-1","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,7]]},"assertion":[{"value":"11 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"898"}}